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Abstract. The oncogene ETS-related gene (ERG) encodes a 
transcription factor with roles in the regulation of haemato-
poiesis, angiogenesis, vasculogenesis, inflammation, migration 
and invasion. The ERG oncogene is activated in >50% of 
prostate cancer cases, generally through a gene fusion with 
the androgen-responsive promoter of transmembrane protease 
serine 2. Phosphatase and tensin homologue (PTEN) is an 
important tumour suppressor gene that is often inactivated in 
cancer. ERG overexpression combined with PTEN inactiva-
tion or loss is often associated with aggressive prostate cancer. 
The present study aimed to determine whether or not ERG 
regulates PTEN transcription directly. ERG was demonstrated 
to bind to the PTEN promoter and repress its transcription. 
ERG overexpression reduced endogenous PTEN expression, 
whereas ERG knockdown increased PTEN transcription. The 
ability of ERG to repress PTEN may contribute to a more 
cancer-permissive environment.
Introduction
Prostate cancer is the most common form of cancer in men. It 
accounts for 10% of malignant tumours worldwide and 13% 
of male cancer deaths in the UK. It is most frequently seen 
in older men, with 80% of cases being diagnosed in the over 
65 years (1). It is estimated that approximately 70% of men 
will develop some form of prostate cancer but the majority of 
cases will not be clinically relevant (2). Prostate cancer is not 
necessarily lethal; it is a multifocal and heterogeneous cancer 
with a wide range of outcomes. Its heterogeneity provides a 
real challenge for accurate prognosis and making appropriate 
treatment decisions (3). The difficulty lies in distinguishing 
between indolent and aggressive forms of the disease. The 
current non-invasive diagnostic test of choice is the PSA 
serum test. However, raised PSA levels can be due to factors 
other than prostate cancer such as benign prostatic hyperplasia 
and inflammation (4,5).
Gleason grading on histopathological examination is 
currently the gold standard prognostic test; however it cannot 
always give a correct prognosis. Inconsistencies arise due 
to differences in sampling procedures, and morphologically 
similar cancers can behave very differently. Approximately 
70-80% of Gleason 6 and 20% of Gleason 7 tumours may be 
non-aggressive and not require intervention for 15 years or 
more (6); conversely, an undetected, aggressive cancer may 
become lethal within 2-12 years (7). Aggressive prostate cancer 
can be treated successfully if caught in early, organ‑confined 
stages. Therefore it is imperative to develop a method able to 
discern indolent cases not requiring immediate intervention 
from the aggressive ones which do. Treatment can have a detri-
mental effect on the patients' quality of life by causing urinary 
and sexual dysfunction (8). Furthermore, approximately 30% 
of patients suffer from disease recurrence with metastases 
subsequent to radical prostatectomy (9).
Prostatic intraepithelial neoplasia (PIN) lesions are benign 
alterations thought to appear approximately 10 years before 
the development of prostatic carcinoma. PIN is often unidenti-
fied as it does not produce high levels of PSA and can only be 
detected by biopsy (3). A marker which could easily detect 
PIN would be extremely useful in both diagnostic and prog-
nostic testing. Much attention has recently focused on a gene 
fusion, TMPRSS2:ETS-related gene (ERG), that is frequently 
found in aggressive prostate cancer. The TMPRRSS2 portion 
of the fusion contains an androgen-responsive promoter which 
drives the aberrant expression of the oncogenic transcription 
factor ERG (10). ERG is involved in homeostasis, survival, 
differentiation, angiogenesis and vasculogenesis (11).
Phosphatase and tensin homologue (PTEN) is one of the 
most studied tumour suppressor genes that influences a wide 
range of cellular processes including survival, proliferation, 
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adhesion, migration, metabolism and differentiation. Loss 
of functional PTEN protein accelerates cancer by allowing 
the PI3K/AKT pathway to be constitutively switched on, 
promoting epithelial-mesenchymal transition (EMT) and 
metastasis (3,12). PTEN is lost or mutated in 50-80% of 
primary prostate cancer (but not in all cases). Its loss is 
involved in tumour initiation, is associated with highly aggres-
sive and metastatic cancer, predicts poor clinical outcome (13), 
and is linked with progression to androgen-independence 
and biochemical recurrence (14). Tumours in which the loss 
of PTEN protein is observed at biopsy are more likely to be 
have higher Gleason scores (15). Thus both ERG and PTEN 
are both especially important players in prostate cancer; but 
the extent to which they might interact is not yet clear. Given 
the presence several potential ERG binding sites in the PTEN 
promoter, we sought to determine whether or not the transcrip-
tion factor ERG might regulate PTEN expression directly.
Materials and methods
Cell culture. The PC3 and LNCaP prostate cancer cell lines, 
and the PNT2 normal prostatic epithelium cell lines were 
maintained in RPMI-1640 and the DU145 and VCaP prostate 
cancer cell lines were maintained in Dulbecco's modified 
Eagle's medium (DMEM; Gibco-Invitrogen, Paisley, UK). All 
media were supplemented with 2 mM L-glutamine + 10% (v/v) 
Donor Bovine Serum (Sigma-Aldrich, Poole, UK). The PC3 
and VCaP cell lines were obtained from the Health Protection 
Agency (HPA)-European Collection of Cell Cultures (ECACC, 
Salisbury, UK). The DU145, LNCaP and PNT2 cell lines were 
kindly provided by Professor Jeff Holly's group (Department 
of Clinical Science at North Bristol, University of Bristol, 
Bristol, UK).
RNA extraction and cDNA synthesis. RNA was extracted using 
the Isolate RNA mini kit (BioLine, London, UK) according 
to the manufacturer's protocols. RNA was quantified using 
a Nanodrop 1000 (Thermo Fisher Scientific, Inc., Waltham, 
MA, USA). A total of 500 ng of RNA was reverse transcribed 
using the cDNA Synthesis kit (BioLine) spiked with 0.2 µg of 
Arabidopsis thaliana RuBisCO RNA exogenous control.
Quantitative polymerase chain reaction (qPCR). qPCR reac-
tions were set up using BioLine's SensiFAST SYBR Hi-ROX 
kit consisting of master mix, primers (0.25 nM each), cDNA 
(6.25 ng) and run on an ABI (Applied Biosystems; Thermo 
Fisher Scientific, Inc.) 7300 qPCR thermal cycler for 95˚C for 
10 min, followed by 95˚C for 15 sec and 60˚C for 1 min for 
40 cycles. Primers were designed using FastPCR software 
(PrimerDigital Ltd., Helsinki, Finland). Data was analysed 
using the relative standard curve method. For each experiment 
a standard curve was generated for both the gene of interest 
and the RuBisCO control. Reverse transcribed control cDNA 
(including the RuBisCO spike) was serially diluted over seven 
points and assigned arbitrary values. These values were then 
converted to log base 10 and plotted against the Ct data points 
for the target gene or RuBisCO to generate a line equation 
y=mx+c. To find the relative log values (x) the following equa-
tion was used: x=Ct-c/m. The antilog was taken to reach the 
original relative values. To calculate the relative abundance, 
target gene values were normalised to their corresponding 
RuBisco values.
Protein extraction and quantitation. Standard RIPA cell lysis 
buffer (20 mM Tris-HCl pH 7.4, with 150 mM NaCl, 0.1% 
SDS, 1% Triton X-100, 1% deoxycholate, 5 mM EDTA) plus 
protease inhibitors (Pierce A32953; Pierce; Thermo Fisher 
Scientific, Inc.) was added to the cells and left to incubate 
on ice for 15 min. Wells were then scraped and the lysate 
homogenised by aspiration using a needle and syringe. Cells 
were pelleted at 14,000 rpm for 10 min at 4˚C in a microcentri-
fuge. Clarified supernatant was then transferred to a fresh tube 
and frozen at -80˚C. Protein quantitation was performed using 
the Pierce BCA (bicinchoninic acid) assay and a Nanodrop 
1000 (Thermo Fisher Scientific, Inc.).
Western blotting. SDS-PAGE was performed according to 
standard procedures (10% acrylamide gels). Immunodetection 
was undertaken with 30 µg of protein lysate using the chemi-
luminescent Luminata Forte kit (Merck Millipore, Watford, 
UK). The ERG primary antibody (rabbit polyclonal, ERG-1/2/3 
(C-20) antibody sc-353; Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA, USA) was used at a dilution of 1:500. The PTEN 
antibody (mouse monoclonal 26H9; Cell Signaling Technology, 
Inc., Danvers, MA, USA) was used at a dilution 1:1,000. 
The secondary horse-radish peroxidise (HRP)-conjugated 
anti-rabbit IgG antibody was used at a 1:6,000 dilution. For 
a loading control a GAPDH primary antibody [rabbit poly-
clonal, GAPDH (sc-25778; Santa Cruz Biotechnology, Inc.) 
was used at a 1:6,000 dilution. Immunoblots were developed 
and imaged using an Amersham Imager 600 (GE Healthcare, 
Buckinghamshire, UK) or LI-COR Odyssey Fc gel-doc 
system. Densitometric analysis of the blots was performed 
using ImageJ software.
Two‑step chromatin immunoprecipitation. Putative ETS 
transcription factor binding sites within the PTEN promoter 
were determined by searching for GGAA or TTCC 
sequences within the promoter's nucleotide sequence (NCBI 
Accession no. AF067844.1). Primers for each gene were 
designed using the FastPCR programme (PrimerDigital 
Ltd.). Chromatin immunoprecipitation was performed on 
extracts derived from the ERG expressing VCaP cell line; 
6x106 cells were seeded into a 100 mm tissue culture dish 
and left to adhere for 72 h. Chromatin immunoprecipitation 
was then carried out using the Champion ChIP Assay kit 
(SABiosciences; Qiagen, Frederick, MD, USA) following the 
manufacturer's recommended protocol but with an additional 
protein‑protein cross‑linking step before formaldehyde fixa-
tion. Cells were fixed in 2 mM disuccinimidyl glutarate 
(DSG) with 1 mM MgCl2 in PBS at room temperature for 
45 min. Cells were then washed in PBS and fixed in 1% form-
aldehyde + 1 mM MgCl2 in PBS (pH 8) and incubated for 
15 min at room temperature. Sonication was performed using 
a MSE Soniprep 150 set at 7 amplitude microns with 4 cycles 
of 15 sec on, 30 sec off. 4 µg of ERG antibody (ERG-1/2/3 
(C-20): sc-353 for ChIP; Santa Cruz Biotechnology, Inc.), 
RNA Pol II antibody (positive control; Sigma-Aldrich) and 
mouse IgG (negative control; Sigma-Aldrich) were used 
in the immunoprecipitations. DNA was extracted from 
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the immunoprecipitate using the GenElute Mammalian 
Genomic DNA Purification kit (Sigma-Aldrich) and ampli-
fied by SYBR-Green qPCR. Primers corresponding to the 
target promoters were as follows (all 5' to 3'): PTEN forward 
tcaacggctatgtgttcacg, and reverse gtcttagcacaaagagcaacctgc 
(163 bp amplicon); IGFBP2 forward tgctgctactgggcgcgagt, 
and reverse acaagtgccctcgcccatgaccag (329 bp). Data was 
analysed using the % input method. Firstly, input Ct was 
adjusted to 100% (Ct input-6.64). Results from immuno-
precipitated samples were analysed using the following 
calculation: 100*2^ (adjusted input-Ct (IP). Fold difference 
was calculated against the negative control (mouse IgG).
Knockdown of ERG through splice‑switching oligonucle‑
otides. Splice-switching oligonucleotides (Vivo-Morpholinos) 
were designed and provided by Gene Tools, LLC (Philomath, 
OR, USA). A standard morpholino control (5'-CCTCTTACC 
TCAGTTACAATTTATA-3') and two Vivo-Morpholinos 
targeting the 3' and 5' splice sites of exon 4 of ERG pre-mRNA 
were used (E43' and E45', respectively, sequences available on 
request). A total of 700,000 VCaP (ATCC CRL-2876) cells 
were seeded into compartments of a 6-well plate and cultured 
at 37˚C for 72 h. Media (DMEM with 10% FBS) was then 
replaced with fresh media containing 0.006% endoporter 
delivery agent (Gene Tools, LLC) and one of the following: 
6 µM standard morphol ino cont rol;  6 µM E45' 
Vivo-Morpholinos; 6 µM E43' Vivo-Morpholinos. After 72 h 
of Morpholino treatment cells were lysed in RIPA buffer 
(20 mM Tris-HCl pH 7.4, with 150 mM NaCl, 0.1% SDS, 
1% Triton X-100, 1% deoxycholate, 5 mM EDTA) plus protease 
inhibitors (Pierce A32953; Pierce; Thermo Fisher Scientific, 
Inc.).
Over‑expression of ERG. A pCMV-SPORT6 plasmid 
containing the full length cDNA clone of ERG variant 1 (acces-
sion no: BC040168) in DH10B TonA cells was purchased from 
Open Biosystems (Thermo Fisher Scientific, Inc., Ashford, 
UK). Cells were revived overnight in 5 ml of lysogeny 
broth with 100 µg/ml ampicillin (Sigma-Aldrich). Plasmids 
were then purified using the PureYield Plasmid Miniprep 
Sytem (Promega Corp., Madison, WI, USA) according to 
the manufacturer's instructions. The day before transfection 
1.0x106 cells per well were seeded into a 6-well plate. After 
24 h the cells were starved for two h in Optimem. Cells were 
then transfected with 2 µg pCMV-SPORT6-ERG DNA with 
transfection reagent (Fugene HD; Promega Corp.) added at a 
ratio of 1:3 (DNA: reagent). Cells were incubated for four h 
and then refreshed in complete media. Cells were transfected 
for up to 72 h, after which cells were subjected to either RNA 
or protein extraction.
Construction of transcription reporter plasmids. The 
promoter constructs for IGF1, IGFBP2 and PTEN were made 
as follows. DNA containing the upstream promoter sequences 
of IGF1, IGFBP2 and PTEN was amplified from human cheek 
cell genomic DNA by PCR using KOD Hot Start DNA poly-
merase (Novagen; Merck Biosciences, Bad Soden, Germany) 
supplemented with 5% (v/v) DMSO final volume. Primers 
were designed to introduce KpnI restriction sites to the at the 
5' end of each amplified fragment. The PCR product was cut 
with KpnI/NcoI, and ligated into KpnI/NcoI digested lucif-
erase-expressing pGL3 plasmid (Promega Corp.). Plasmids 
were transformed into E. coli (Topo cloning kit; Invitrogen; 
Thermo Fisher Scientific, Inc.) amplified and purified. The 
promoter sequences were verified by restriction analysis and 
sequencing (DNA Sequencing and Services; University of 
Dundee, Dundee, Scotland).
Dual‑luciferase transcription assay. DU145 and VCaP cells 
were transfected using the method previously described (over-
expression of ERG). Promoter constructs were transfected at 
400 ng per well in a 12-well plate along with 40 ng of pRLTk 
Renilla-expressing plasmid as an internal control or 400 ng 
promoter + 40 ng Renilla + 0-1000 ng pCMVSport6-ERG. 
Untransfected cells were used as a control for background 
fluorescence. The dual‑luciferase assay kit (Promega Corp.) 
was used according to the manufacturer's instructions and 
luminescence measured using a Centro XS LB 960 Microplate 
Luminometer and Microwin2000 software (BERTHOLD 
TECHNOLOGIES GmbH & Co. KG, Bad Wildbad, Germany). 
Read-outs for untreated cells were subtracted from query 
sample readings to remove background noise. Query samples 
were normalised against Renilla out-puts, normalised query 
results were compared to control samples (promoter construct 
only). Results were calculated as fold differences.
siRNA‑mediated ERG knockdown combined with DLR assay. 
At 72 h before transfection VCaP ((ATCC CRL-2876) cells 
were seeded at 1.0x106 cells per well in a 6-well plate. On 
the day of transfection, cells were starved in reduced-serum 
medium (Optimem; Invitrogen; Thermo Fisher Scientific, 
Inc.) for 2 h then followed by transfection with 100 nM 
ERG-targeting siRNA (Qiagen) or non-targeting siRNA 
(allstars negative control, Qiagen). Cells were incubated for 
four h before removal of the transfection media and replace-
ment with complete media. Cells were transfected for up to 
120 h, then subjected to dual-luciferase assays, as described 
above.
Results and Discussion
ERG is a member of the ETS family of transcription factors 
that share a DNA-binding domain termed the ETS-binding 
domain (EBD). The EBD is an 85 amino-acid domain that 
forms a winged helix-turn-helix motif that binds to DNA 
sequences that contain a core GGAA/T sequence (18). ERG 
has been shown to bind to this core sequence (19).
The cell line VCaP, established from a vertebral metastasis, 
retains PTEN expression and is positive for the TMPRSS2:ERG 
fusion (20). We first confirmed that ERG is expressed exclu-
sively in VCaP cells And that PTEN is expressed in VCaP, 
DU145 and LNCaP cells (Fig. 1). We examined the PTEN 
promoter and identified several clusters of GGAA sequences 
ranging from 1,300 bp upstream to 500 downstream of the 
transcription start site (Fig. 2C). We performed a ChIP (chro-
matin immunoprecipitation) assay using extracts from VCaP 
cells and observed that ERG interacts with the PTEN promoter 
(Fig. 2). As a positive control an antibody against RNA poly-
merase II co-precipitated with the PTEN promoter (as PTEN 
is expressed in VCaP cells). We also looked at whether the 
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ERG antibody could co-precipitate with another promoter that 
contains putative ETS binding sites, and examined IGFBP2. 
Only the PTEN promoter co-precipitated with ERG.
Having obtained evidence that ERG interacts with the 
PTEN promoter, we transfected DU145 prostate cancer 
cells (ERG negative and PTEN positive) with a plasmid that 
expresses full length ERG. After 24-48 h we observed a 
significant increase in ERG expression; this was confirmed by 
qPCR and western blotting (Fig. 3). At 48 h post-transfection 
we observed a significant reduction in PTEN expression 
both at the RNA and protein level in cells transfected with 
the ERG expressing plasmid compared to the control. Next 
we determined whether the knockdown of ERG resulted 
in an upregulation of PTEN. To knockdown ERG in VCaP 
cells we used a splice switching oligonucleotide (SSO) 
approach. Morpholino SSOs were generated against both 
the 5' and 3' splice sites of ERG's exon 4. Transfection of 
the SSOs results in exon 4 skipping (data not shown). Exon 4 
skipping creates a premature stop codon which leads to 
nonsense mediated decay and a resulting drop in ERG 
protein. Reduction of ERG protein achieved with the exon 4 
SSOs resulted in a clear increase of PTEN protein.
Taken together these results clearly suggested that ERG 
transcriptionally represses PTEN. To obtain further evidence 
to confirm this we fused the PTEN promoter to a luciferase 
reporter plasmid for use in a dual-luciferase:Renilla (DLR) 
Figure 1. Expression of ERG in representative prostate cancer cell lines. (A) ERG transcript levels were normalised to a spiked exogenous plant mRNA 
(RuBisCO). The TMPRSS2:ERG positive VCaP cell line expressed high levels of ERG. In contrast ERG mRNA was barely detected in PC3, DU145 and LNCaP 
cells. (B) PTEN transcript levels were similarly normalised to plant RuBisCO. PTEN mRNA was detected in all cell lines except the PTEN-/-PC3 cells (27). 
(C) ERG protein was also detected by western blotting in VCaP cells, but not in PC3 or PNT2 (normal prostate epithelium) cell lines. 20 µg total cell extract 
was loaded into each well. ERG, ETS-related gene; PTEN, phosphatase and tensin homologue.
Figure 2. Chromatin immunoprecipitation of PTEN and IGFBP2 promoters with an anti-ERG antibody in the VCaP cell line. The signal was normalised to a 
control mouse IgG. (A) For the PTEN promoter, the RNA Pol II signal was 15.38 (+0.32; P>0.0001) relative to the control, whereas the ERG signal was 7.53 
(+0.72; P>0.001). There was no significant binding of ERG to the promoter of IGFBP2 (B). (C) Putative ERG binding sites in the promoter region of human 
PTEN promoter. GGAA (black diamonds; +strand) and the reverse complement TTCC are shown (grey diamonds; -strand). ERG, ETS-related gene; PTEN, 
phosphatase and tensin homologue
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transcription assay. We co-transfected increasing amounts 
of the ERG expressing plasmid (0-1,000 ng) with 1 µg of 
the PTEN promoter:luciferase construct in DU145 cells. We 
observed a progressive reduction in PTEN promoter activity 
with increasing amounts of co-transfected ERG expressing 
plasmid (Fig. 4A). To extend these findings, we also trans-
fected the PTEN promoter:luciferase construct into VCaP cells 
(which express both ERG and PTEN) and then knocked-down 
ERG in VCaP cells using two independent siRNAs, observing 
in each case a significant increase in the activity of the PTEN 
promoter (Fig. 4B).
The interest in ERG as a potential biomarker of prostate 
cancer has grown since the first report of its over‑expression 
in clinical prostate cancer samples (10). The fusion with the 
TMPRSS2 promoter allows ERG expression to be driven by 
androgens. At the same time the literature indicates clearly that 
loss of expression of the PTEN tumour suppressor gene is also 
linked to the progression of prostate cancer. Mice that overex-
press ERG and lack PTEN expression develop prostate tumours 
by the age of six months, further confirming the synergy 
between these two genetic alterations (21). PTEN deletions 
tend to occur after ERG activation-it has also been suggested 
that ERG might itself drive the development of PTEN aberra-
tions (22). However it is also clear that the upregulation of ERG 
and the deletion of PTEN expression can occur independently 
and do not always occur in the same tumour (23).
In the current study we sought to look into the possibility 
that the transcription factor ERG affects the expression of 
PTEN directly. We present evidence that ERG represses PTEN 
transcription in DU145 and VCaP prostate cancer cells. By 
repressing the transcription of PTEN, ERG could help cancer 
development by activating the AKT/PI3K pathway, increasing 
angiogenesis, proliferation, invasion, motility and metastasis. 
This finding may have broader significance because ERG 
is not exclusively associated with prostate cancer. ERG is 
also implicated in leukaemia where it is linked to chemo-
resistance (24,25). The ability of ERG to repress PTEN 
transcription in leukaemia, or in other types of cancer, remains 
to be investigated.
Figure 3. Effect of ERG overexpression in DU145 and knockdown in VCaP cells on PTEN expression. (A) Expression of ERG in DU145 cells was measured 
by qPCR, relative to 18S rRNA, 24 and 48 h post-transfection. There was no detectable expression in the control (empty vector) transfection compared to cells 
transfected with ERG‑expressing plasmid (ERG O/E). (B) ERG overexpression caused a significant decrease in PTEN expression. (C) A reduction of PTEN 
expression as a result of ERG overexpression was also confirmed by western blotting. Three replicate experiments are shown; increased ERG protein levels 
correspond in each case to reduced PTEN levels. (D) ERG expression was knocked down in VCaP cells using splice-switching morpholino oligonucleotides 
(SSOs, provided by Gene Tools, LLC) directed against the 5' and 3' splice sites of exon 4. ERG knockdown resulted in increased endogenous PTEN expression. 
A control SSO did not affect ERG or PTEN expression. A total of 6 µM of morpholino was transfected in each experiment. (C and D) A total of 20 µg of protein 
were loaded into each track. ERG, ETS-related gene; PTEN, phosphatase and tensin homologue.
Figure 4. Dual-luciferase assay demonstrating transcriptional repression of 
PTEN by ERG. (A) ERG expressing plasmid (0-1,000 ng) was co-transfected 
into DU145 cells with a PTEN promoter fused to a luciferase reporter (400 
ng; pGL3 vector) and a Renilla internal control (40 ng). (B) ERG was knocked 
down in VCaP cells using two independent siRNAs (ERG KD1 and KD2; 
NS, non‑specific siRNA). The ratio of luciferase to Renilla signal is shown. 
N=3 repeats in each case. ERG, ETS-related gene; PTEN, phosphatase and 
tensin homologue.
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ERG, like the vast majority of human genes, is alternatively 
spliced. We recently reported in advanced prostate cancer an 
increased inclusion rate of exons that encode the CAE domain 
in the middle of ERG (26). The CAE domain is thought to 
modulate ERG's transcriptional activities. Future experiments 
will compare the extent to which ERG splice isoforms can 
repress PTEN transcription and whether or not ERG's repres-
sion of PTEN plays a role in the development of aggressive 
prostate cancer.
In summary, the ability of ERG to repress the transcrip-
tion of a critically important tumour suppressor such as PTEN 
further implicates ERG in carcinogenesis and underlines its 
clear potential as a diagnostic marker and therapeutic target.
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